Trial · NCT07064902
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07064902, Phase 2, Not yet recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma. Trials, record NCT07064902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07064902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
- NCT number
- NCT07064902
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Nasopharyngeal Carcinoma (NPC)
- Interventions
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- First posted
- 2025-07-15
- Last updated
- 2026-07-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete response rate (CRR) | At the end of induction therapy | Disappearance of all target lesions, with all pathological lymph nodes (including both target and non-target nodes) reduced in short axis to less than 10 mm. |
| Secondary | Objective response rate (ORR) | At the end of induction therapy | Objective Response Rate (ORR) is defined as the proportion of patients who achieve either a Complete Response (CR) or a Partial Response (PR) as assessed per RECIST v1.1 criteria. |
| Secondary | Failure-free survival (FFS) | 2 years | calculated from enrolment to the date of locoregional recurrence, distant metastasis, or death from any cause, whichever occurred first. |
| Secondary | Overall survival (OS) | 2 years | calculated from enrolment to the date of death from any cause. |
| Secondary | Distant metastasis-free survival (DMFS) | 2 years | calculated from enrolment to the date of first distant metastasis. |
| Secondary | Locoregional recurrence-free survival (LRRFS) | 2 years | calculated from enrolment to the date of locoregional persistence or 1st locoregional recurrence. |
| Secondary | Adverse events (AEs) and serious adverse events (SAEs) | 2 years | Analysis of adverse events (AEs) are based on treatmentrelated AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. Graded according to CTCAE V5.0. |
| Secondary | Quality of life (QoL) | 2 years | Change in quality of life (QoL) will be assessed at six time points: prior to enrollment (baseline), after completion of induction immunotherapy, after completion of concurrent chemoradiotherapy, after the 5th cycle of adjuvant immunotherapy, after completion of all adjuvant immunotherapy, and at 6 months following the end of adjuvant immunotherapy. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), version 3.0, will be used. This validated instrument contains 30 items, of which 24 are grouped into nine multi-item scales: five functional scales, three symptom scales, and one global health status/QoL scale. The remaining six items are single-item symptom scales. All 15 scales will be scored according to the EORTC QLQ-C30 Scoring Manual.Each scale is linearly transformed to a 0-100 scale. Higher scores indicate better functioning and QoL on functional and global health scales, but worse symptoms on symptom scales. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07064902
GET https://conductscience.org/api/trials/v1/NCT07064902/registered